Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alpine Immune Sciences, Inc. (NASDAQ: ALPN).

Full DD Report for ALPN

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALPN)

Alpine Immune Sciences beats by $0.02
Alpine Immune Sciences (NASDAQ: ALPN ): Q1 EPS of -$0.38 beats by $0.02 . Cash, cash equivalents, and short-term investments of $76.7M Press Release More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 14 2018 16:31
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and reported financial results for the ...
Source: Business Wire
Date: May, 14 2018 16:00
Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant
A great business at a fair price is superior to a fair business at a great price. - Charlie Munger Alpine Immune Sciences (NASDAQ: ALPN ) is a highly promising grower that we recently featured in the prior research. Despite its nascent history, the company owns two highly valuable ther...
Source: SeekingAlpha
Date: May, 11 2018 02:25
Alpine: Explicating The Upcoming Catalysts Powering Robust Potential For This Stock
Instead of looking for success, make a list of how to fail instead. Tell me where I’m going to die, that is, so I don’t go there. - Charlie Munger At Integrated BioSci Investing , we rarely feature coverage on a small firm unless its prospects are gargantuan. In breaking o...
Source: SeekingAlpha
Date: May, 10 2018 03:07
Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an experienced life sciences executive, currently serves as the Chief Executive Officer of Flashlight Therapeutics. “We are pleased to have Chris join Al...
Source: Business Wire
Date: April, 24 2018 07:00
Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model
-- ALPN-202 is a potential novel immuno-oncology therapy providing dual PD-L1/CTLA-4 antagonism with CD28 costimulation -- -- Unique mechanism seeks to address lack of costimulatory activity of existing immuno-oncology therapies -- -- Data Presented at 2018 American Association fo...
Source: Business Wire
Date: April, 17 2018 14:00
Blog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell Program
Stock Monitor: Alpine Immune Sciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on ImmunoCellular Therapeutics, Ltd (NYSE: IMUC ) ("ImmunoCellular"). If you want access to this report all you need ...
Source: ACCESSWIRE IA
Date: April, 16 2018 07:50
Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators
Don’t be afraid of buying on a war scare. Through the entire twentieth century, with a single exception, every time major war has broken out anywhere in the world or whenever American forces have become involved in any fighting, whatever, the American stock market has always plunged s...
Source: SeekingAlpha
Date: April, 13 2018 00:14
An Integrated BioSci Report On Alpine Immune Sciences: A Stellar Next-Generation Immunotherapy Innovator
We select such investments on a long-term basis, weighing the same factors as would be involved in the purchase of 100% of an operating business: (1) favorable long-term economic characteristics; (2) competent and honest management; (3) purchase price attractive when measured against t...
Source: SeekingAlpha
Date: April, 01 2018 03:18
Alpine Immune Sciences reports FY results
Alpine Immune Sciences (NASDAQ: ALPN ): FY EPS of -$1.20 More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 28 2018 07:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-188.178.819.258.1726,804
2018-05-178.178.819.258.1726,804

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1710,01752,97918.9075Cover
2018-08-162,1702,89674.9309Short
2018-08-151,7659,27519.0296Cover
2018-08-141,8478,95820.6184Cover
2018-08-1350490455.7522Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALPN.


About Alpine Immune Sciences, Inc. (NASDAQ: ALPN)

Logo for Alpine Immune Sciences, Inc. (NASDAQ: ALPN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $109,107,142 - 05/11/2018
  • Issue and Outstanding: 13,846,084 - 03/20/2018

 


Recent Filings from (NASDAQ: ALPN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 24 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 28 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 28 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: January, 26 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: January, 26 2018

 

 


Daily Technical Chart for (NASDAQ: ALPN)

Daily Technical Chart for (NASDAQ: ALPN)


Stay tuned for daily updates and more on (NASDAQ: ALPN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALPN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALPN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALPN and does not buy, sell, or trade any shares of ALPN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/